Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections
Sebastian Wendt, Donald Ranft, Arne C. Rodloff, Norman Lippmann, Christoph Lübbert
Abstract
infection (CDI) rates and various antimicrobials' application densities from 2013 to 2019 at Leipzig University Hospital, Germany, by using multivariate linear regression. Ceftriaxone application was the only independent predictor of CDI incidence. Thus, antibiotics' specific pharmacokinetic and pharmacodynamic properties such as biliary excretion of ceftriaxone in its active form should be considered when determining their potential to cause CDI.
Topics & Concepts
MedicineClostridioidesCeftriaxoneCefotaximeFidaxomicinInternal medicineC difficileClostridium difficileAntibioticsIntensive care medicineMicrobiologyVancomycinBacteriaBiologyGeneticsStaphylococcus aureusClostridium difficile and Clostridium perfringens researchMicroscopic ColitisNosocomial Infections in ICU